Grainne O'Kane

Medical Oncologist; clinical and translational researcher pancreatic and hepatobiliary cancers. Views are my own 🇮🇪🇨🇦

[LARVOL @Larvol]

@myESMO 2026: Top trending GI cancer oncologists on 𝕏

Explore #ESMO26 insights here: https://t.co/JBaV2QEuxu

#LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer #ClinicalOncology | @Erman_Akkus | @GIMedOnc | @DraMartinezLago | @GillSharlene | @DaisukeKotani | @ilyassahinMD | @TapiaJC1 | @ArndtVogel | @Aiims1742 | @YannickBuccella | @DrAngelaLamarca | @CathyEngMD | @pashtoonkasi | @graokane | @UGrewalMD

[Grainne O'Kane @graokane]

OPTIMUM rand ph2 adv #BTC
➡️dx control on plat- olaparib v olaparib/durva
➡️somatic/ germline DDR but wide range genes
➡️❗️BRCA1/2/PALB2 ~30% (⬆️Olap arm)
❎no diff 6mth PFS
❎1yr OS rate 64 v76%
❗️we must define true HRD in trials & understand TME
@myESMO #ESMO26 @OncoAlert

[Grainne O'Kane @graokane]

Final analysis LEAP012 unresectable #HCC TACE +Len/Pembro v TACE
➡️mPFS 14.6 v 10.2 HR 0.7
➡️ORR 71 v 49% by mRECIST
❎mOS 40.4 v 40.6; ~1/3 in both subsequent tx
❎much higher gd3/4 TRAEs 71%v31%
➡️❗️1/3 BCLCA
➡️Role combo unclear consistent -ve OS
@myESMO #ESMO26 @OncoAlert

[Grainne O'Kane @graokane]

🔥Ph2 Peri-operative RASi (HRS-4642, G12D)+ GnP +/-adebrelimab (PD-L1)
➡️two cohorts n=60 #PDAC
➡️safety- mainly haem, none precluded surgery
➡️ORR 63% & 87%;MPR in 17%
➡️R0 resection rate 100%
✅6 mth EFS rate 87% & 96%
➡️100% ⬇️CA19.9; OS pending
@myESMO #ESMO26 @OncoAlert

[Grainne O'Kane @graokane]

INCB161734 KRASG12D (ON/OFF) + GnP or mFFX; updated ph1, n=53
➡️mostly GI toxicity,dose intensity 85% with GnP & 77%mFFX
✅ORR 69%, DCR 96% GnP
✅ORR 89%, DCR 100% mFFX
➡️6 mth PFS rates 80% & 90%
⭐️impressive & can combine mFFX
✅DAWN-303 ph3 ongoing
@myESMO #ESMO26 @OncoAlert

[Mairead G McNamara, MB PhD, FASCO @MGMcNamara]

Intrahepatics doing best with GBC and extra hepatic OS HR not as favourable; GBC definitely different biology, with HR similar to TOPAZ in this primary site; more research needed @CharityAMMF @PrecisionBTCnet @curecc

[Grainne O'Kane @graokane]

🔥HARMONi-GI1 ph3 advanced #BTC
➡️ivonescimab/GC v durva/GC mFU 14.3mths; China only & interim
✅ iCCA 58% ORR 53.8v32.5%; mPFS 8.4 v 5.8mths
✅mOS 14.9 v12.1mths HR0.75
➡️AE rate high in both
Control arm OS represents❗️VEGF in BTC ⭐️ looks promising
@myESMO #ESMO26 @OncoAlert

[Grainne O'Kane @graokane]

Masterful talk @BasGrootKoerkam on localised #PDAC & #BTC 🔑points👇
➡️PDAC staging requires anatomy/biology/clinical ass
➡️?older patients benefit NAC
➡️hilar obs➡️perc stenting TESLA
➡️high risk iCCA consider NAC
➡️LRT & Liver tx evolving in iCCA
@myESMO #ESMO26 @OncoAlert

[Grainne O'Kane @graokane]

GFH276 pan-RAS (ON) molecular glue
➡️ph1/1b data; n=73 PDAC ,5-320mg
➡️no . prior lines tx =2
➡️ORR 41% in #PDAC, @ 40-160mg,
small nos with prior RASi
➡️Rash most common AE
As many trials move quickly to 1st line, how will we sequence??
@myESMO #ESMO26 @OncoAlert

[Lorenza Rimassa @LorenzaRimassa]

Today I had the honor to discuss two important abstracts of novel treatment approaches for patients with #HCC across different stages and settings at #ESMO26. Not yet in clinical practice, but clinically relevant results. #ESMOAmbassadors @myESMO @HUNIMED @HumanitasMilano

[Grainne O'Kane @graokane]

🔥Promising #HCC BGB-B2033
➡️GPC3 x 4-1BB bispecific ph1/2 more mature data
➡️dose escalation/optimisation
activity across all: 2/3rd >2 prior lines
ORR ~36%
➡️450mg selected R2PD; very favourable toxicity
➡️Phase 3 GroundBBreaker 301 due to open
@myESMO #ESMO26 @OncoAlert

[Grainne O'Kane @graokane]

Much anticipated ACTICCA-1
➡️adj cis/gem v cape #BTC
➡️mod ITT n=591
➡️no diff in DFS at 24mth 52% v 44%
RMST at 3 yrs ⬆️DFS by 2.6mth
➡️28% iCCA -no maj subgroup diff
➡️mOS 58.1 v 48.2 p=0.1
❎No change to std ?an option, NB need as backbone 1st line!
@myESMO @OncoAlert #ESMO26

[Grainne O'Kane @graokane]

Paclitaxel +\-tovecimig: COMPANION-002 ph2/3
➡️prev treated #BTC wo actionable alterations
➡️ORR 17.1 v5.3%; DCR 62 v 37%
➡️mPFS 4.7 v 2.6mths - benefits seen at PFS2 noting crossover
➡️OS not sig but nb crossover
@myESMO #ESMO26 @OncoAlert

[Grainne O'Kane @graokane]

MASTERPLAN randomised ph2
➡️chemo(90% mFFX) +\-SBRT localised #PDAC
➡️included potentially operable high risk /BR &LAPC not operable
➡️primary endpoint 12mth LRR :20% v 52%
➡️more R0 resections with SBRT
➡️mPFS 11.9 v6.3mth; mOS 22 v 14mth
@myesmo #ESMO26 @oncoalert

[Grainne O'Kane @graokane]

And we are 🚀 #ESMO26 🔝GI abstracts! 👇

[OncoAlert @OncoAlert]

🚨 #ESMO26 GI Cancer: Top Ten by @OncoAlert 🧬

From organ preservation in dMMR rectal and gastric cancer to RAS(ON) inhibition in pancreatic cancer and bispecifics in biliary tract cancer, our faculty picked the must-know GI abstracts from Madrid 👇

#GICancer #CRCSM
@CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara , @pashtoonkasi
, @GillSharlene

[Grainne O'Kane @graokane]

AMPLIFY-7P randomised ph2
✅7-valent(camupepimut) mKRAS lymph node targeted amphiphile
➡️curative intent & no recurrence <6mth #PDAC
✅T cell responses,primary endpt-ve
➡️benefit in ctDNA-ve& no rads?
➡️DFS @6mth benefit of 14% p=0.056
✅ph3 planned
@myESMO @OncoAlert #ESMO26